Fuji Pharma
Biosimilar developer, Japan. 5 development products across 5 molecules: aflibercept, denosumab, filgrastim, golimumab, ustekinumab.
First approval in the Atlas: Nov 2012, Filgrastim BS F / Mochida, filgrastim (PMDA)
FDAproducts approved0
EMAproducts approved0
PMDAproducts approved5
HCproducts approved0
CDSCOproducts approved0
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Aflibercept | Aflibercept BS NIT | · | · | Sep 2025 | · | · | · |
| Denosumab | Denosumab BS F | · | · | Sep 2025 | · | · | · |
| Filgrastim | Filgrastim BS F / Mochida | · | · | Nov 2012 | · | · | · |
| Golimumab | Golimumab BS F | · | · | Sep 2025 | · | · | · |
| Ustekinumab | Ustekinumab BS F | · | · | Sep 2023 | · | · | · |
Month shown is the first approval or registration of that product in that market.
Chronology
- PMDANov 2012Filgrastim BS F / Mochida, filgrastim
- PMDASep 2023Ustekinumab BS F, ustekinumab
- PMDASep 2025Aflibercept BS NIT, aflibercept
- PMDASep 2025Denosumab BS 120 mg RM F, denosumab
- PMDASep 2025Golimumab BS F, golimumab
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.